Tigecycline Use: Indications, Dosing, and Adjustments
Critical Safety Warning
Tigecycline carries a black box warning for increased all-cause mortality (0.6% absolute risk increase) and should be reserved only for situations when alternative treatments are not suitable. 1 It is specifically NOT indicated for hospital-acquired pneumonia, ventilator-associated pneumonia, or diabetic foot infections due to demonstrated increased mortality and decreased efficacy. 1
FDA-Approved Indications (Adults ≥18 years)
Tigecycline is approved for three specific infections 1:
Complicated skin and skin structure infections (cSSSI)
- Causative organisms: E. coli, E. faecalis (vancomycin-susceptible), S. aureus (MRSA/MSSA), Streptococcus species, Enterobacter cloacae, K. pneumoniae, B. fragilis
Complicated intra-abdominal infections (cIAI)
- Causative organisms: Citrobacter freundii, E. cloacae, E. coli, Klebsiella species, E. faecalis, S. aureus, anaerobes including Bacteroides and Clostridium species
Community-acquired bacterial pneumonia (CABP)
- Causative organisms: S. pneumoniae (penicillin-susceptible), H. influenzae, Legionella pneumophila
Standard Adult Dosing Regimen
Loading dose: 100 mg IV over 30-60 minutes
Maintenance dose: 50 mg IV every 12 hours over 30-60 minutes 1
Treatment duration:
- cSSSI and cIAI: 5-14 days
- CABP: 7-14 days
- Duration guided by infection severity, site, and clinical response
Dose Adjustments
Hepatic Impairment 1
- Child-Pugh A (mild): No adjustment needed
- Child-Pugh B (moderate): No adjustment needed
- Child-Pugh C (severe):
- Loading dose: 100 mg IV
- Maintenance dose: 25 mg IV every 12 hours (50% reduction)
- Monitor closely for treatment response
Renal Impairment 1
No dose adjustment required regardless of creatinine clearance. Tigecycline is not significantly removed by hemodialysis.
Obesity 2
No dose adaptation is recommended for patients with obesity. Available data suggest standard dosing achieves adequate exposures without weight-based adjustments.
Age 1
No dose adjustment needed for elderly patients. No significant difference in exposure between elderly and younger subjects.
Off-Label Use in Multidrug-Resistant Organisms
Carbapenem-Resistant Enterobacterales (CRE) 3
For bloodstream infections:
- Tigecycline 100 mg IV loading, then 50 mg IV q12h (Weak recommendation, Very low evidence - 2D)
- Typically used in polymyxin-based combinations:
- Colistin + Tigecycline, OR
- Tigecycline + Meropenem (extended infusion)
- Duration: 7-14 days
For complicated intra-abdominal infections:
- Tigecycline 100 mg IV loading, then 50 mg IV q12h (2D)
- Duration: 5-7 days
Vancomycin-Resistant Enterococci (VRE) 3
For complicated intra-abdominal infections:
- Tigecycline 100 mg IV loading, then 50 mg IV q12h (Weak recommendation, Very low evidence - 2D)
- Duration: 5-7 days (individualized based on source control and response)
High-Dose Considerations for Resistant Pathogens
Recent evidence suggests standard dosing may be inadequate for certain resistant organisms 4, 5, 6:
High-dose regimen for drug-resistant infections, VAP, or cSSSI with resistant pathogens:
- Loading dose: 100-200 mg IV
- Maintenance dose: 100 mg IV every 12 hours
This applies particularly to:
- K. pneumoniae with MIC >2 mg/L
- E. cloacae
- A. baumannii
- Ventilator-associated pneumonia (off-label, use with extreme caution given mortality concerns)
Consider combination therapy for severe infections with resistant organisms rather than monotherapy. 3
Pediatric Dosing (Use Only When No Alternatives Available) 3, 1
Avoid tigecycline in patients <18 years unless absolutely no alternative exists due to mortality concerns and lack of safety/efficacy data.
If unavoidable:
- Ages 8-11 years: 1.2 mg/kg IV q12h (maximum 50 mg/dose)
- Ages 12-17 years: 50 mg IV q12h (adult dose)
- No data for hepatic impairment in pediatrics
Key Clinical Pitfalls
- Do not use for hospital-acquired/ventilator-associated pneumonia - associated with increased mortality 1
- Do not use for diabetic foot infections - failed to demonstrate non-inferiority 1
- Nausea and vomiting are extremely common (28.5% and 19.4% respectively) - consider prophylactic antiemetics 7, 8
- Standard dosing may fail for resistant Gram-negatives - consider high-dose regimens for MIC >2 mg/L 5, 6
- Not active against Pseudomonas aeruginosa or Proteus species 9
- Infectious disease consultation strongly recommended when using for multidrug-resistant organisms 3